Omada is trading publicly after 14 years of providing support to patients with weight-related chronic illnesses. Leadership sees the current moment as the perfect time for an IPO, as GLP-1 drugs such ...

The European Medicines Agency's safety committee has concluded that the use of Novo Nordisk's popular weight-loss drug Wegovy ...